Sunshine Biopharma (SBFM) Projected to Announce Quarterly Earnings on Thursday

Sunshine Biopharma (NASDAQ:SBFM) is projected to announce its results before the market opens on Thursday, November 12th. Analysts expect Sunshine Biopharma to post earnings of ($3.40) per share and revenue of $9.60 million for the quarter.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($23.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($24.00) by $1.00. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. The firm had revenue of $9.26 million during the quarter, compared to the consensus estimate of $8.70 million. On average, analysts expect Sunshine Biopharma to post ($39.00) EPS for the current fiscal year and ($8.00) EPS for the next fiscal year.

Sunshine Biopharma Stock Performance

Shares of Sunshine Biopharma stock opened at $2.75 on Tuesday. The stock’s fifty day moving average is $11.64 and its 200 day moving average is $102.06. The stock has a market cap of $605,000.00, a P/E ratio of -0.01 and a beta of 1.32. Sunshine Biopharma has a one year low of $2.53 and a one year high of $464.00.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SBFM. Wall Street Zen raised shares of Sunshine Biopharma to a “hold” rating in a research note on Saturday, October 31st. Weiss Ratings upgraded shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sunshine Biopharma currently has an average rating of “Reduce”.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.

In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.